{
  "id": 19585236,
  "title": "United Therapeutics CEO sells $4.76M in stock after option exercise",
  "url": "https://urgent.news/2026/11/12/united-therapeutics-ceo-sells-4-76m-in-stock-after-option-exercise",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T02:01:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-ceo-sells-476m-in-stock-after-option-exercise-93CH-5020182"
  },
  "original_language": "en",
  "account": "United Therapeutics' CEO Martine A. Rothblatt sold 9,500 shares of the company's stock on September 16, 2026, for a total of $4,763,172. This sale came after Rothblatt exercised stock options for the same number of shares as part of a pre-arranged trading plan. The company's stock price has surged 29% over the past year, reaching $595.66, close to its 52-week high of $614.23. At the time of the stock options exercise, Rothblatt bought 9,500 shares at $117.76 per share, paying $1,118,720. These options had been vested between March 2021 and March 2023. Immediately following the option exercise, Rothblatt sold off the 9,500 shares at prices between $498.45 and $505.20, generating the aforementioned total proceeds. All transactions were carried out under a Rule 10b5-1 trading plan, which is set to continue until 1,734,410 options are exercised or December 31, 2026, whichever occurs first. After these transactions, Rothblatt indirectly owns 324,443 shares through a family trust, along with shares held by her spouse and other family trusts. Despite the stock being deemed overvalued by InvestingPro, analysts see potential in United Therapeutics. The stock is currently trading near its recent peak, with investors potentially interested in a Pro Research Report on UTHR to gain deeper insights. Meanwhile, United Therapeutics reported record third-quarter revenue of $832.5 million, exceeding expectations, although earnings per share fell short of projections. The company's outlook was boosted by strong demand for Tyvaso and other products, leading various analysts to raise their price targets and maintain positive ratings.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}